Remission of anxiety diagnoses: long‐term · children and adolescents with anxiety disorders
CBT showed no clear difference in remission of anxiety diagnoses: long‐term compared with wait‐list (low certainty).
1 finding from 1 review
Reduction in anxiety symptoms (parent report) post‐treatment · children and adolescents with anxiety disorders
Remission of anxiety diagnoses (ITT analysis) i.e. no longer meeting criteria for DSM or ICD anxiety diagnosis at the end of the trial. · children and adolescents with anxiety disorders
CBT showed no clear difference in remission of anxiety diagnoses (ITT) analysis i.e. no longer meeting… compared with active controls (moderate certainty).
1 finding from 1 review
Remission of anxiety diagnoses (ITT analysis) i.e. no longer meeting criteria for DSM or ICD anxiety diagnosis at the end of the trial. · children and adolescents with anxiety disorders
CBT showed no clear difference in remission of anxiety diagnoses (ITT analysis) i.e. no longer meeting… compared with treatment (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of participants waiting longer than recommended · patients scheduled for elective surgery
1 finding from 1 review
no estimate extracted
1 participants
Very low
Pain (short‐ and long‐term) Scale from 0 to 100 (lower is better) · patients with osteoarthritis
1 finding from 1 review
Physical function · patients with osteoarthritis
1 finding from 1 review
Composite Measure of Pain, Function and Disability as · patients with osteoarthritis
1 finding from 1 review
Pain on a 0 to 100 scale ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
1 finding from 1 review
WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
Chondroitin leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term… compared with placebo (high certainty).
1 finding from 1 review
Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d Scale: millimeters (smaller decrease in reduction in minimum joint space width is better) · patients with osteoarthritis
1 finding from 1 review
Pain (short‐ and long‐term) Scale from 0 to 100 mm (lower is better) · patients with osteoarthritis
1 finding from 1 review
WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
Chondroitin with or without glucosamine leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) Long‐term… compared with placebo/control (high certainty).
1 finding from 1 review
All‐cause mortality ‐ long‐term · Anyone diagnosed with AMI
Cells showed no clear difference in all‐cause mortality ‐ long‐term compared with no cells (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · Anyone diagnosed with AMI
Cells showed no clear difference in cardiovascular mortality ‐ long‐term compared with no cells (moderate certainty).
1 finding from 1 review
Composite death, reinfarction and hospitalisation for heart failure ‐ long‐term · Anyone diagnosed with AMI
Cells showed no clear difference in composite death, reinfarction and hospitalisation for heart failure… compared with no cells (moderate certainty).
1 finding from 1 review
Longer‐term maternal outcomes: failure to breastfeed · women with a twin pregnancy
Planned caesarean section showed no clear difference in longer‐term maternal outcomes: failure to breastfeed compared with planned vaginal birth (moderate certainty).
1 finding from 1 review
Postnatal depression · women with a twin pregnancy
Planned caesarean section showed no clear difference in longer‐term maternal outcomes: postnatal depression, as defined by… compared with planned vaginal birth (moderate certainty).
1 finding from 1 review
Survival (long term) Over two years · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in survival (long term) Over two years compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Has died · critically ill patients
Early probably leads to lower mortality at longest compared with late tracheostomy (moderate certainty).
1 finding from 1 review